Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 15.02.17 in Vol 6, No 2 (2017): February

This paper is in the following e-collection/theme issue:

Works citing "VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials"

Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce KH Chow, Valérie Vilgrain

JMIR Res Protoc 2017 (Feb 15); 6(2):e17 

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.7016):

(note that this is only a small subset of citations)

  1. Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma RA, Walk A. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. JMIR Research Protocols 2020;9(4):e16296
    CrossRef
  2. Justinger C, Gruden J, Kouladouros K, Stravodimos C, Reimer P, Tannapfel A, Binnenhei M, Bentz M, Tatsch K, Rüdiger T, Schön MR. Histopathological changes resulting from selective internal radiotherapy (SIRT). Journal of Surgical Oncology 2018;117(5):1084
    CrossRef
  3. Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Seminars in Radiation Oncology 2020;30(1):68
    CrossRef
  4. Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncology 2020;16(1):4315
    CrossRef
  5. Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technology Assessment 2020;24(48):1
    CrossRef
  6. Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han K, Seong J, Won JY, Han DH, Kim BK.

    Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

    . Journal of Hepatocellular Carcinoma 2020;Volume 7:403
    CrossRef
  7. Rizzo A, Ricci AD, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7(1):1
    CrossRef
  8. . Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?. Future Oncology 2022;18(14):1665
    CrossRef
  9. Elaimy AL, Cao Y, Lawrence TS. Evolution of Response-Based Radiotherapy for Hepatocellular Cancer. The Cancer Journal 2023;29(5):266
    CrossRef